Global Meningococcal Vaccine Market Growth 2023-2029

Global Meningococcal Vaccine Market Growth 2023-2029

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

LPI (LP Information)' newest research report, the “Meningococcal Vaccine Industry Forecast” looks at past sales and reviews total world Meningococcal Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Meningococcal Vaccine sales for 2023 through 2029. With Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Meningococcal Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Vaccine.

The global Meningococcal Vaccine market size is projected to grow from US$ 256.3 million in 2022 to US$ 350.3 million in 2029; it is expected to grow at a CAGR of 350.3 from 2023 to 2029.

Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.

Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.

In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.

This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Meningtits A

Polysaccharide Meningtitis AC

Meningitis ACYW

Segmentation by application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novartis

GSK

Merck

CSL

Baxter

JN International Medical Corporation

Serum Institute of India

Bio-Med

China National Biotec Group

Hualan Bio

Walvax

Zhifei

Key Questions Addressed in this Report

What is the 10-year outlook for the global Meningococcal Vaccine market?

What factors are driving Meningococcal Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Meningococcal Vaccine market opportunities vary by end market size?

How does Meningococcal Vaccine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.